Literature DB >> 11739616

The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons.

S K Michelhaugh1, C Fiskerstrand, E Lovejoy, M J Bannon, J P Quinn.   

Abstract

The dopamine (DAT) and serotonin (SERT) transporter genes both contain variable number of tandem repeats (VNTR) in non-coding gene regions which have been correlated with a predisposition to a variety of CNS disorders. There is considerable homology between individual DAT and SERT repeat DNA sequences, which is reflected in their ability to compete with each other for specific protein binding as demonstrated by electrophoretic mobility shift assay. The SERT VNTR has recently been shown to act as a transcriptional enhancer. Because of the similarities between SERT and DAT VNTRs, the DAT VNTR may also enhance transcription. This study demonstrates by lipid transfection into an immortalized dopaminergic cell line and biolistic transfection into dopamine neurons in neonatal rat midbrain slices that the human nine-repeat DAT VNTR can enhance transcription. This enhancing activity suggests that the DAT VNTR may play a role in regulation of DAT gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739616     DOI: 10.1046/j.1471-4159.2001.00647.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  47 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  An association study on the polymorphisms of dopaminergic genes with working memory in a healthy Chinese Han population.

Authors:  Pingyuan Gong; Hang Zhang; Wanyu Chi; Wanhua Ge; Kejin Zhang; Anyun Zheng; Xiaocai Gao; Fuchang Zhang
Journal:  Cell Mol Neurobiol       Date:  2012-02-24       Impact factor: 5.046

Review 3.  Early institutionalization: neurobiological consequences and genetic modifiers.

Authors:  Margaret Sheridan; Stacy Drury; Kate McLaughlin; Alisa Almas
Journal:  Neuropsychol Rev       Date:  2010-11-03       Impact factor: 7.444

Review 4.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

5.  Association of dopamine transporter gene variants with childhood ADHD features in bipolar disorder.

Authors:  Tiffany A Greenwood; Eun-Jeong Joo; Tatyana Shekhtman; A Dessa Sadovnick; Ronald A Remick; Paul E Keck; Susan L McElroy; John R Kelsoe
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-12-19       Impact factor: 3.568

6.  The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study.

Authors:  Mindi A Styn; Tomoko Nukui; Marjorie Romkes; Kenneth Perkins; Stephanie R Land; Joel L Weissfeld
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-03-05       Impact factor: 3.568

7.  The role of the dopamine transporter (DAT) in the development of PTSD in preschool children.

Authors:  Stacy S Drury; Katherine P Theall; Bronya J B Keats; Michael Scheeringa
Journal:  J Trauma Stress       Date:  2009-12

8.  Attention-Deficit Hyperactivity Disorder in the post-genomic era.

Authors:  Philip Asherson
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

9.  The dopamine transporter gene, a spectrum of most common risky behaviors, and the legal status of the behaviors.

Authors:  Guang Guo; Tianji Cai; Rui Guo; Hongyu Wang; Kathleen Mullan Harris
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

10.  Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population.

Authors:  Alicja Sieminska; Krzysztof Buczkowski; Ewa Jassem; Marek Niedoszytko; Ewa Tkacz
Journal:  BMC Med Genet       Date:  2009-09-17       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.